Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
Novosibirsk State University, Novosibirsk, Russia.
Anticancer Res. 2020 Feb;40(2):795-805. doi: 10.21873/anticanres.14011.
BACKGROUND/AIM: We previously have described the "3+1" tumors cure approach consisting of individual time schedule of cyclophosphamide and dsDNA preparation administrations. The aim of the study was to adapt the "3+1" approach based on eradication of cancer stem cells to the model of murine ascitic cyclophosphamide-resistant lymphosarcoma (RLS).
Adaptation of the "3+1" approach includes the identification of the timing to disrupt the tumorigenic potential of a certain tumor.
The proposed therapeutic scheme allowed complete reduction of primary RLS ascites in experimental animals. However, reduction of primary ascites due to the complementary action of cyclophosphamide and dsDNA was inevitably followed by the development of a secondary one, most likely arising from a solid carcinomatous formation in the peritoneal wall.
The "3+1" approach resulted in the elimination of cancer stem cells, and, as a consequence, in the complete reduction of RLS ascites.
背景/目的：我们之前描述了“3+1”肿瘤治愈方法，该方法包括环磷酰胺和 dsDNA 制剂的个体化时间安排。本研究的目的是基于消除肿瘤干细胞，将“3+1”方法应用于小鼠腹腔环磷酰胺耐药淋巴肉瘤（RLS）模型。
“3+1”方法的适应包括确定破坏特定肿瘤致瘤潜力的时间。
所提出的治疗方案使实验动物中原发性 RLS 腹水完全减少。然而，由于环磷酰胺和 dsDNA 的互补作用导致原发性腹水减少，不可避免地会继发继发性腹水，这很可能是由于腹膜壁中的实体癌形成。
“3+1”方法导致了肿瘤干细胞的消除，从而导致 RLS 腹水的完全减少。
